Enhancing stereotactic radiation schedules using the vascular disrupting agent OXi4503

被引：0
|
作者：
Horsman, M. R. [1 ]
Wittenborn, T. R. [1 ]
机构：
[1] Aarhus Univ Hosp, Dept Clin Oncol, Aarhus C, Denmark
来源：
RADIOTHERAPY AND ONCOLOGY | 2016年 / 119卷
关键词：
D O I：
10.1016/S0167-8140(16)31484-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OC-0235
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [1] COMBINING THE VASCULAR DISRUPTING AGENT OXI4503 WITH RADIATION IN A CONVENTIONAL OR STEREOTACTIC FRACTIONATED RADIATION SCHEDULE
    Horsman, M. R.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S76 - S76
  • [2] Phase I evaluation of vascular disrupting agent OXi4503
    Patterson, D. M.
    Charnley, N.
    Saleem, A.
    Stratford, M.
    Dickinson, C.
    Asselin, M.
    Ross, P.
    Walicke, P.
    Price, P.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS
    Stockton, Shannon Somer
    Pettiford, Leslie
    Cline, Christina
    Chaplin, David
    Hsu, Jack W.
    Wingard, John R.
    Cogle, Christopher R.
    [J]. BLOOD, 2015, 126 (23)
  • [4] Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation
    Horsman, Michael R.
    [J]. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2015, 31 (05) : 453 - 459
  • [5] Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
    Salmon, Howard W.
    Siemann, Dietmar W.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 4090 - 4094
  • [6] Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
    Patterson, D. M.
    Ross, P.
    Koetz, B.
    Saleem, A.
    Stratford, M.
    Stirling, J.
    Padhani, A.
    Asselin, M.
    Price, P.
    Rustin, G. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer
    Bothwell, Katelyn D.
    Folaron, Margaret
    Seshadri, Mukund
    [J]. CANCERS, 2016, 8 (01)
  • [8] Interim results from a phase I trial of the vascular disrupting agent OXi4503
    Patterson, Daniel M.
    Ross, Phillip
    Koetz, Barbara
    Saleem, Azeem
    Stratford, Mike
    Stirling, James
    Padhani, Anwar
    Asselin, Marie-Claude
    Price, Pat
    Rustin, Gordon J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3436S - 3436S
  • [9] Activity of the vascular disrupting agent Oxi4503 against an acute myelogenous leukemia xenograft model
    Siim, Bronwyn
    Walicke, Patricia
    Chaplin, David
    [J]. CANCER RESEARCH, 2009, 69
  • [10] Evaluating the Potential of OXi4503 to Enhance Tumour Response to Radiation Administered in Clinically Relevant Conventional or Stereotactic Schedules
    Horsman, M. R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 192 - 192
12345